Why is there no feedback on pge2/setipiprant? 10/7/2016
The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Setipiprant/PGE2 feedbacks?
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
community SETIPIPRANT PGE2 GROUP BUY AND PIONEERING HAIR GROWTH
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
community Best, possible, or experimental growth agonists that AREN'T MINOXIDIL.
Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.
community Setipiprant study updated on ClinicalTrials - anticipated May 9th completion
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
community The New, Improved CB-03-01/Setipiprant Group Buy
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Related Research
6 / 6 resultsresearch The physiological and pharmacological roles of prostaglandins in hair growth
This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.
research The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case‐controlled study
This study found that topical cetirizine treatment significantly improved hair regrowth and patient satisfaction in male patients with androgenetic alopecia compared to a placebo, highlighting its potential role in treatment.
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research A review of the treatment of male pattern hair loss
This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.
research The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
This review discusses the potential roles of prostaglandin D2 and its receptor CRTH2 in various diseases beyond allergies and asthma and reports no new clinical results.